We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
BUPRENORPHINE SANDOZ (Sandoz Pty Ltd)
Product name
BUPRENORPHINE SANDOZ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
171 working days (255)
Active ingredients
buprenorphine
Registration type
New generic medicine
Indication
BUPRENORPHINE SANDOZ (dermal patch) is indicated for management of moderate to severe pain.